Product Information

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.1828 per EA under NDC 00378300277. Its NADAC has been published 652 times since Nov 28, 2013.

The High Outlier badge above means this manufacturer's average price in the candesartan cilexetil and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB

candesartan cilexetil and hydrochlorothiazide
$1.1828per EA
Discontinued
High Outlier

Strength

32; 12.5 mg/1; mg/1

NDC

00378300277

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

5/20/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA090704

On Market Since

12/4/2012

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has been published 652 times since Nov 28, 2013, and over the history we have for it it has declined 29.5%. The table below summarizes its recorded NADAC range and movement.

Current price$1.1828 per EA
All-time high$3.7501 (Jan 11, 2017)
All-time low$0.7888 (Nov 20, 2024)
52-week high$1.2226
52-week low$1.0214
Median price$1.8792
Average price$2.0112
Largest weekly change+63.0% (Jul 20, 2016)
Weeks tracked652
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

0.0%

3M

+0.8%

6M

+14.0%

1Y

+11.7%

3Y

-31.1%

5Y

-44.2%

All

-29.5%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $1.1828 per EA (NDC 00378300277), effective May 20, 2026.

How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB changed over time?

Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has declined 29.5%. It has been tracked across 652 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

Since Nov 28, 2013, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has ranged from a low of $0.7888 (Nov 20, 2024) to a high of $3.7501 (Jan 11, 2017), with a median of $1.8792 per EA.

Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, is $1.0569 per EA — about 11% below CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB.

Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB (NDC 00378300277) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.